EC
HRTX icon

EntryPoint Capital’s Heron Therapeutics HRTX Stock Holding History

EntryPoint Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,252
Closed -$30.4K – 833
2024
Q3 		$30.4K Buy
+15,252
New +$36.4K 0.02% 593

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EntryPoint Capital's HRTX Position: Q4 2024 in Review

EntryPoint Capital sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 15,252 shares — an estimated $30.4K sold.

EntryPoint Capital first reported a position in HRTX in Q3 2024 and held it in 1 quarter. The position peaked at $30.4K in Q3 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • EntryPoint Capital reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 15,252 Heron Therapeutics shares in Q4 2024, an estimated $30.4K.
  • EntryPoint Capital first reported a position in Heron Therapeutics in Q3 2024 and held it in 1 quarter.
  • EntryPoint Capital's Heron Therapeutics position peaked at $30.4K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.